热景生物(688068) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 reached ¥963,492,898.68, representing a year-on-year increase of 391.95%[5] - The net profit attributable to shareholders for Q3 2022 was ¥286,732,319.22, an increase of 1,108.80% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥279,157,578.66, up 1,362.08% year-on-year[5] - Year-to-date revenue as of Q3 2022 was ¥3,009,179,202.30, showing a decrease of 20.72% compared to the same period last year[5] - Year-to-date net profit attributable to shareholders was ¥1,101,511,599.04, down 25.39% year-on-year[5] - Basic earnings per share for the current reporting period is 1,108.80 yuan, attributed to an increase in net profit attributable to shareholders[12] - The net profit attributable to the parent company for Q3 2022 was approximately ¥1.10 billion, a decrease of 25.4% compared to ¥1.48 billion in Q3 2021[25] - The basic and diluted earnings per share for Q3 2022 were both ¥11.97, down from ¥16.04 in the same period last year[26] - The total comprehensive income for Q3 2022 was approximately ¥1.11 billion, compared to ¥1.48 billion in Q3 2021, reflecting a decrease of 25.5%[25] Research and Development - The company's R&D investment totaled ¥56,489,528.50 in Q3 2022, an increase of 152.78% compared to the same period last year[6] - The R&D investment as a percentage of operating revenue was 5.86%, a decrease of 5.55 percentage points year-on-year[6] - Total R&D investment for the current reporting period is 152.78 million, mainly due to increases in patent and registration fees, as well as employee compensation[12] - Research and development expenses for the first three quarters of 2022 were CNY 138,276,090.40, up from CNY 82,749,843.72 in 2021, indicating a growth of 67.3%[24] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥3,928,415,132.55, reflecting a growth of 7.78% from the end of the previous year[6] - Total assets increased to CNY 3,928,415,132.55 as of September 30, 2022, compared to CNY 3,644,844,550.64 at the end of 2021, marking an increase of 7.8%[21] - Total liabilities decreased significantly to CNY 348,124,598.11 from CNY 771,014,749.09, a reduction of 54.8%[21] - Shareholders' equity attributable to the company's shareholders increased by 24.48% at the end of the reporting period compared to the end of the previous year, due to an increase in net profit[12] Cash Flow - The company reported a net cash flow from operating activities of ¥708,980,431.99 year-to-date, down 47.55% compared to the previous year[6] - The net cash flow from operating activities for the year-to-date period is -47.55 million, primarily due to a decrease in cash received from sales and services[12] - Cash flow from operating activities for the first nine months of 2022 was ¥2.80 billion, a decline of 27.1% from ¥3.84 billion in the first nine months of 2021[27] - The net cash flow from operating activities for Q3 2022 was ¥708.98 million, down 47.5% from ¥1.35 billion in Q3 2021[28] - The net cash flow from investing activities for the first nine months of 2022 was -¥860.66 million, an improvement from -¥1.32 billion in the same period last year[28] - The company received cash from investment activities totaling ¥2.26 billion in the first nine months of 2022, compared to ¥2.46 billion in the same period of 2021[28] - The company reported a cash outflow from financing activities of ¥417.50 million in the first nine months of 2022, compared to ¥101.70 million in the same period last year[28] Current and Non-Current Assets - The company’s total current assets decreased to CNY 2,216,954,153.41 from CNY 2,517,680,486.33, a decline of 11.9%[19] - The company’s total non-current assets increased to CNY 1,711,460,979.14 as of September 30, 2022, compared to CNY 1,127,164,064.31 at the end of 2021, reflecting an increase of 51.7%[20] - Cash and cash equivalents decreased to CNY 627,247,709.25 as of September 30, 2022, from CNY 1,161,059,870.24 at the end of 2021, representing a decline of 46.0%[19] - Cash and cash equivalents at the end of Q3 2022 were ¥596.78 million, a decrease from ¥316.75 million at the end of Q3 2021[28] Investment Activities - The company reported a significant increase in long-term equity investments to CNY 173,651,875.25 as of September 30, 2022, compared to CNY 151,599,554.36 at the end of 2021, an increase of 14.6%[19] - The company did not report any net profit from subsidiaries prior to consolidation in the current or previous periods[26]